Abstract
Purpose
The development of diagnostic and therapeutic agents utilizing small peptides (e.g., bombesin (BBN)) to target the overexpression of the gastrin-releasing peptide receptor (GRPR) in cancers has been widely investigated. Herein, we examine the capabilities of BBN-modified HPMA copolymers to target the GRPR.
Methods
Four positive, four negative, and two zwitterionic BBN HPMA copolymer conjugates of varying peptide content and charge were synthesized. In vitro and in vivo studies were conducted in a GRPR-overexpressing prostate cancer cell line (PC-3) and a normal CF-1 mouse model, respectively.
Results
Cellular uptake of the conjugates were found to be charge and BBN density dependent. The positively-charged conjugates illustrated a direct relationship between the extent of cellular internalization, ranging from 0.7 to 20%, and BBN-incorporation density. The negative and zwitterionic conjugates showed low PC-3 uptake values. Blocking studies confirmed the GRPR-targeting effect of the positively-charged constructs. In vivo studies of the positively-charged copolymers resulted in rapid blood clearance by the mononuclear phagocyte system (MPS)-associated tissues (e.g., liver and spleen).
Conclusion
Positively-charged BBN-HPMA copolymer conjugates demonstrated good GRPR-targeting and internalization in vitro. However, the impact of peptide density and charge on in vivo MPS recognition are parameters that must be optimized in future agent development.
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs11095-020-02952-3/MediaObjects/11095_2020_2952_Fig1_HTML.png)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs11095-020-02952-3/MediaObjects/11095_2020_2952_Fig2_HTML.png)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs11095-020-02952-3/MediaObjects/11095_2020_2952_Fig3_HTML.png)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs11095-020-02952-3/MediaObjects/11095_2020_2952_Fig4_HTML.png)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs11095-020-02952-3/MediaObjects/11095_2020_2952_Fig5_HTML.png)
Similar content being viewed by others
Abbreviations
- BBN:
-
Bombesin
- BBN-EE:
-
Bombesin peptide modified with two negatively charged amino acids
- BBN-RR:
-
Bombesin peptide modified with two positively charged amino acids
- GRPR:
-
Gastrin releasing peptide receptor
- P-D-RR:
-
HPMA copolymer modified with D-BBN-RR
- P-EE:
-
HPMA copolymer modified with BBN-EE
- P-RR:
-
HPMA copolymer modified with BBN-RR
- P-RREE:
-
HPMA copolymer modified with BBN-RR and BBN-EE
References
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30.
Markwalder R, Reubi JC. Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation. Cancer Res. 1999;59(5):1152–9.
Yu Z, Ananias HJ, Carlucci G, Hoving HD, Helfrich W, Dierckx RA, et al. An update of radiolabeled bombesin analogs for gastrin-releasing peptide receptor targeting. Curr Pharm Des. 2013;19(18):3329–41.
Moreno P, Ramos-Alvarez I, Moody TW, Jensen RT. Bombesin related peptides/receptors and their promising therapeutic roles in cancer imaging, targeting and treatment. Expert Opin Ther Targets. 2016;20(9):1055–73.
Aloj L, Attili B, Lau D, Caraco C, Lechermann LM, Mendichovszky IA, Harper I, Cheow H, Casey RT, Sala E. The emerging role of cell surface receptor and protein binding radiopharmaceuticals in cancer diagnostics and therapy. Nuclear Medicine and Biology. 2020.
Accardo A, Galli F, Mansi R, Del Pozzo L, Aurilio M, Morisco A, et al. Pre-clinical evaluation of eight DOTA coupled gastrin-releasing peptide receptor (GRP-R) ligands for in vivo targeting of receptor-expressing tumors. EJNMMI Res. 2016;6(1):17.
Hoppenz P, Els-Heindl S, Beck-Sickinger AG. Identification and stabilization of a highly selective gastrin-releasing peptide receptor agonist. J Pept Sci. 2019;25(12):e3224.
Kurth J, Krause BJ, Schwarzenbock SM, Bergner C, Hakenberg OW, Heuschkel M. First-in-human dosimetry of gastrin-releasing peptide receptor antagonist [(177)Lu]Lu-RM2: a radiopharmaceutical for the treatment of metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2020;47(1):123–35.
Zhang J, Niu G, Fan X, Lang L, Hou G, Chen L, et al. PET using a GRPR antagonist (68)Ga-RM26 in healthy volunteers and prostate Cancer patients. J Nucl Med. 2018;59(6):922–8.
Wieser G, Mansi R, Grosu AL, Schultze-Seemann W, Dumont-Walter RA, Meyer PT, et al. Positron emission tomography (PET) imaging of prostate cancer with a gastrin releasing peptide receptor antagonist--from mice to men. Theranostics. 2014;4(4):412–9.
Rizzo LY, Theek B, Storm G, Kiessling F, Lammers T. Recent progress in nanomedicine: therapeutic, diagnostic and theranostic applications. Curr Opin Biotechnol. 2013;24(6):1159–66.
Lammers T, Aime S, Hennink WE, Storm G, Kiessling F. Theranostic nanomedicine. Acc Chem Res. 2011;44(10):1029–38.
Soares S, Sousa J, Pais A, Vitorino C. Nanomedicine: principles, properties, and regulatory issues. Front Chem. 2018;6:360.
Maeda H. Toward a full understanding of the EPR effect in primary and metastatic tumors as well as issues related to its heterogeneity. Adv Drug Deliv Rev. 2015;91:3–6.
Bertrand N, Wu J, Xu X, Kamaly N, Farokhzad OC. Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. Adv Drug Deliv Rev. 2014;66:2–25.
Chanda N, Kattumuri V, Shukla R, Zambre A, Katti K, Upendran A, et al. Bombesin functionalized gold nanoparticles show in vitro and in vivo cancer receptor specificity. Proc Natl Acad Sci U S A. 2010;107(19):8760–5.
Lee C-M, Jeong H-J, Cheong S-J, Kim E-M, Kim DW, Lim ST, et al. Prostate cancer-targeted imaging using magnetofluorescent polymeric nanoparticles functionalized with bombesin. Pharm Res. 2010;27(4):712–21.
Li R, Gao R, Wang Y, Liu Z, Xu H, Duan A, et al. Gastrin releasing peptide receptor targeted nano-graphene oxide for near-infrared fluorescence imaging of oral squamous cell carcinoma. Sci Rep. 2020;10(1):1–12.
Cai H, Xie F, Mulgaonkar A, Chen L, Sun X, Hsieh J-T, Peng F, Tian R, Li L, Wu C. Bombesin functionalized 64Cu-copper sulfide nanoparticles for targeted imaging of orthotopic prostate cancer. Nanomedicine. 2018(0), 13.
Kirpotin DB, Drummond DC, Shao Y, Shalaby MR, Hong K, Nielsen UB, et al. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res. 2006;66(13):6732–40.
Schmidt MM, Wittrup KD. A modeling analysis of the effects of molecular size and binding affinity on tumor targeting. Mol Cancer Ther. 2009;8(10):2861–71.
Chytil P, Koziolová E, Etrych T, Ulbrich K. HPMA copolymer–drug conjugates with controlled tumor-specific drug release. Macromol Biosci. 2018;18(1):1700209.
Kopeček J, Kopečková P. HPMA copolymers: origins, early developments, present, and future. Adv Drug Deliv Rev. 2010;62(2):122–49.
Fan W, Zhang W, Jia Y, Brusnahan SK, Garrison JC. Investigation into the biological impact of block size on Cathepsin S-degradable HPMA copolymers. Mol Pharm. 2017;14(5):1405–17.
Fan W, Shi W, Zhang W, Jia Y, Zhou Z, Brusnahan SK, et al. Cathepsin S-cleavable, multi-block HPMA copolymers for improved SPECT/CT imaging of pancreatic cancer. Biomaterials. 2016;103:101–15.
Pike DB, Ghandehari H. HPMA copolymer-cyclic RGD conjugates for tumor targeting. Adv Drug Deliv Rev. 2010;62(2):167–83.
Allmeroth M, Moderegger D, Gündel D, Buchholz HG, Mohr N, Koynov K, et al. PEGylation of HPMA-based block copolymers enhances tumor accumulation in vivo: a quantitative study using radiolabeling and positron emission tomography. J Control Release. 2013;172(1):77–85.
Allmeroth M, Moderegger D, Biesalski B, Koynov K, Rösch F, Thews O, et al. Modifying the body distribution of HPMA-based copolymers by molecular weight and aggregate formation. Biomacromolecules. 2011;12(7):2841–9.
Omelyanenko V, Kopeckova P, Gentry C, Kopecek J. Targetable HPMA copolymer-adriamycin conjugates. Recognition, internalization, and subcellular fate. J Control Release. 1998;53(1–3):25–37.
Li C, Winnard PT, Takagi T, Artemov D, Bhujwalla ZM. Multimodal image-guided enzyme/prodrug cancer therapy. J Am Chem Soc. 2006;128(47):15072–3.
Buckway B, Frazier N, Gormley AJ, Ray A, Ghandehari H. Gold nanorod-mediated hyperthermia enhances the efficacy of HPMA copolymer-90Y conjugates in treatment of prostate tumors. Nucl Med Biol. 2014;41(3):282–9.
Yi Y, Kim HJ, Mi P, Zheng M, Takemoto H, Toh K, et al. Targeted systemic delivery of siRNA to cervical cancer model using cyclic RGD-installed unimer polyion complex-assembled gold nanoparticles. J Control Release. 2016;244:247–56.
Yang M, Gao H, Zhou Y, Ma Y, Quan Q, Lang L, et al. 18F-labeled GRPR agonists and antagonists: a comparative study in prostate cancer imaging. Theranostics. 2011;1:220–9.
Zhang W, Fan W, Ottemann BM, Alshehri S, Garrison JC. Development of improved tumor-Residualizing, GRPR-targeted agents: preclinical comparison of an Endolysosomal trapping approach in agonistic and antagonistic constructs. J Nucl Med. 2020;61(3):443–50.
Mccormick LA, Seymour LC, Duncan R, Kopecek J. Interaction of a cationic N-(2-hydroxypropyl) methacrylamide copolymer with rat visceral yolk sacs cultured in vitro and rat liver in vivo. J Bioact Compat Polym. 1986;1(1):4–19.
Gustafson HH, Holt-Casper D, Grainger DW, Ghandehari H. Nanoparticle uptake: the phagocyte problem. Nano Today. 2015;10(4):487–510.
Montet X, Weissleder R, Josephson L. Imaging pancreatic cancer with a peptide− nanoparticle conjugate targeted to normal pancreas. Bioconjug Chem. 2006;17(4):905–11.
Etrych T, Šubr V, Strohalm J, Šírová M, Říhová B, Ulbrich K. HPMA copolymer-doxorubicin conjugates: the effects of molecular weight and architecture on biodistribution and in vivo activity. J Control Release. 2012;164(3):346–54.
Baratto L, Jadvar H, Iagaru A. Prostate cancer theranostics targeting gastrin-releasing peptide receptors. Mol Imaging Biol. 2018;20(4):501–9.
de Aguiar FC, Fuscaldi LL, Townsend DM, Rubello D, de Barros ALB. Radiolabeled bombesin derivatives for preclinical oncological imaging. Biomed Pharmacother. 2017;87:58–72.
Li L, Yang Q, Zhou Z, Zhong J, Huang Y. Doxorubicin-loaded, charge reversible, folate modified HPMA copolymer conjugates for active cancer cell targeting. Biomaterials. 2014;35(19):5171–87.
Liu J, Bauer H, Callahan J, Kopeckova P, Pan H, Kopecek J. Endocytic uptake of a large array of HPMA copolymers: elucidation into the dependence on the physicochemical characteristics. J Control Release. 2010;143(1):71–9.
He C, Hu Y, Yin L, Tang C, Yin C. Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles. Biomaterials. 2010;31(13):3657–66.
Gu F, Zhang L, Teply BA, Mann N, Wang A, Radovic-Moreno AF, et al. Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers. Proc Natl Acad Sci. 2008;105(7):2586–91.
Varasteh Z, Mitran B, Rosenström U, Velikyan I, Rosestedt M, Lindeberg G, et al. The effect of macrocyclic chelators on the targeting properties of the 68Ga-labeled gastrin releasing peptide receptor antagonist PEG2-RM26. Nucl Med Biol. 2015;42(5):446–54.
Volková M, Mandikova J, Lázníčková A, Lázníček M, Bárta P, Trejtnar F. The involvement of selected membrane transport mechanisms in the cellular uptake of 177Lu-labeled bombesin, somatostatin and gastrin analogues. Nucl Med Biol. 2015;42(1):1–7.
Gibbens-Bandala B, Morales-Avila E, Ferro-Flores G, Santos-Cuevas C, Meléndez-Alafort L, Trujillo-Nolasco M, et al. 177Lu-Bombesin-PLGA (paclitaxel): a targeted controlled-release nanomedicine for bimodal therapy of breast cancer. Mater Sci Eng C. 2019;105:110043.
Patel S, Kim J, Herrera M, Mukherjee A, Kabanov AV, Sahay G. Brief update on endocytosis of nanomedicines. Adv Drug Deliv Rev. 2019;144:90–111.
Shan D, Li J, Cai P, Prasad P, Liu F, Rauth AM, et al. RGD-conjugated solid lipid nanoparticles inhibit adhesion and invasion of α v β 3 integrin-overexpressing breast cancer cells. Drug delivery and translational research. 2015;5(1):15–26.
Alkilany AM, Zhu L, Weller H, Mews A, Parak WJ, Barz M, et al. Ligand density on nanoparticles: a parameter with critical impact on nanomedicine. Adv Drug Deliv Rev. 2019;143:22–36.
Nanda PK, Pandey U, Bottenus BN, Rold TL, Sieckman GL, Szczodroski AF, et al. Bombesin analogues for gastrin-releasing peptide receptor imaging. Nucl Med Biol. 2012;39(4):461–71.
Salouti M, Saghatchi F. BBN conjugated GNPs: a new targeting contrast agent for imaging of breast cancer in radiology. IET Nanobiotechnol. 2017;11(5):604–11.
Shi W, Ogbomo SM, Wagh NK, Zhou Z, Jia Y, Brusnahan SK, et al. The influence of linker length on the properties of cathepsin S cleavable 177Lu-labeled HPMA copolymers for pancreatic cancer imaging. Biomaterials. 2014;35(22):5760–70.
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
ESM 1
(DOCX 3290 kb)
Rights and permissions
About this article
Cite this article
Alshehri, S., Fan, W., Zhang, W. et al. In Vitro Evaluation and Biodistribution Studies of HPMA Copolymers Targeting the Gastrin Releasing Peptide Receptor in Prostate Cancer. Pharm Res 37, 229 (2020). https://doi.org/10.1007/s11095-020-02952-3
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s11095-020-02952-3